Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$3.9B

Dec1Thu

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer treatment. Operating in the healthcare sector, it plays a crucial role in advancing medical solutions that can potentially improve patient outcomes in oncology.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In the last quarter, Legend Biotech reported an EPS of -0.16, which was better than the expected -0.29, resulting in a positive surprise. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Legend Biotech are mixed, with investors looking for signs of growth in its therapeutic offerings. The lack of analyst estimates adds to the uncertainty surrounding the upcoming earnings report.

Bull Case

If the company demonstrates strong progress in its clinical trials or announces new partnerships, it could significantly boost investor confidence and drive the stock price higher.

Bear Case

Conversely, if the earnings report reveals continued losses without a clear path to profitability, it could lead to a decline in stock value as investors reassess their outlook.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of clinical trials for key therapies?

The outcome of these trials is critical for assessing the company's future revenue potential and market position.

Are there any updates on partnerships or collaborations?

New partnerships could enhance the company's capabilities and market reach, which is vital for growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential impact of ongoing clinical trials, which could lead to unexpected positive results.

Supporting Evidence

The company has a history of beating EPS estimates, which could indicate stronger performance than anticipated.

Options pricing suggests a lower expected move compared to historical averages, indicating potential for a larger reaction.

Key Risk

If clinical trial results exceed expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on the company's ability to demonstrate progress in its therapeutic developments and strategic collaborations.

Bull Confirmed If

A significant update on clinical trial progress or new partnerships could validate the bull case.

Bear Confirmed If

Failure to provide any positive updates on clinical trials or partnerships could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing in a 5% move in either direction, indicating that traders expect some volatility following the earnings report.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests the stock could rise by an average of 1.71% on the following day, confirming positive market sentiment.

In-Line / Cautious

Should the results come in line with expectations, the market may react cautiously, leading to a muted response.

Miss

If the company misses expectations, history suggests a potential decline of around 6.91% in stock price, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Details on any new partnerships or collaborations.
3Management's outlook on future revenue growth.
4Any changes in the competitive landscape affecting the company.
5Insights into operational efficiencies and cost management.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If the company demonstrates strong progress in its clinical trials or announces new partnerships, it could significantly boost investor confidence and drive the stock price higher.

Bear Case

Conversely, if the earnings report reveals continued losses without a clear path to profitability, it could lead to a decline in stock value as investors reassess their outlook.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of clinical trials for key therapies?

The outcome of these trials is critical for assessing the company's future revenue potential and market position.

Are there any updates on partnerships or collaborations?

New partnerships could enhance the company's capabilities and market reach, which is vital for growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential impact of ongoing clinical trials, which could lead to unexpected positive results.

Supporting Evidence

The company has a history of beating EPS estimates, which could indicate stronger performance than anticipated.

Options pricing suggests a lower expected move compared to historical averages, indicating potential for a larger reaction.

Key Risk

If clinical trial results exceed expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on the company's ability to demonstrate progress in its therapeutic developments and strategic collaborations.

Bull Confirmed If

A significant update on clinical trial progress or new partnerships could validate the bull case.

Bear Confirmed If

Failure to provide any positive updates on clinical trials or partnerships could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing in a 5% move in either direction, indicating that traders expect some volatility following the earnings report.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests the stock could rise by an average of 1.71% on the following day, confirming positive market sentiment.

In-Line / Cautious

Should the results come in line with expectations, the market may react cautiously, leading to a muted response.

Miss

If the company misses expectations, history suggests a potential decline of around 6.91% in stock price, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Details on any new partnerships or collaborations.
3Management's outlook on future revenue growth.
4Any changes in the competitive landscape affecting the company.
5Insights into operational efficiencies and cost management.